{"id":98,"date":"2026-02-12T12:18:21","date_gmt":"2026-02-12T11:18:21","guid":{"rendered":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/?page_id=98"},"modified":"2026-09-28T17:04:04","modified_gmt":"2026-09-28T15:04:04","slug":"thursday-october-1","status":"publish","type":"page","link":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/program\/thursday-october-1\/","title":{"rendered":"Thursday, October 1st"},"content":{"rendered":"
\r\n \r\n
\r\n
09:30 – 09:40<\/div>\r\n\t\t
\r\n\t\t\t

Introduction and welcome<\/p>\r\n\t\t<\/div>\r\n <\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t09:40 – 10:55<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 1<\/strong> Anemia as a clinical problem, its impact on quality of life, and its role as a prognostic factor<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
\r\n\t\t\t

PART 1 |<\/span> Myelofibrosis: what are new drugs contributing to clinical practice?<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Valent\u00edn Garc\u00eda Guti\u00e9rrez,<\/p>\r\n\t\t\t\t

Hospital Universitario Ram\u00f3n y Cajal. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Gilberto Barranco,<\/p>\r\n\t\t\t\t

Hospital General de M\u00e9xico. Mexico City<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Carlos Plaza,<\/p>\r\n\t\t\t\t

UEES Clinic y SOLCA. Guayaquil, Ecuador<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
09:40 – 10:00<\/div>\r\n\t\t
\r\n\t\t\t

Redefining the treatment algorithm for myelofibrosis<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Blanca Xicoy,<\/p>\r\n\t\t\t\t

ICO – Hospital Germans Trias i Pujol. Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
10:00 – 10:20<\/div>\r\n\t\t
\r\n\t\t\t

The challenge of new treatments for myelofibrosis<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Valent\u00edn Garc\u00eda Guti\u00e9rrez,<\/p>\r\n\t\t\t\t

Hospital Universitario Ram\u00f3n y Cajal. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
10:20 – 10:40<\/div>\r\n\t\t
\r\n\t\t\t

Targeting mutated CALR in myelofibrosis: from molecular biology to clinical application<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Gonzalo Carre\u00f1o,<\/p>\r\n\t\t\t\t

Hospital Universitario 12 de Octubre. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
10:40 – 10:55<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
10:55 – 11:25<\/div>\r\n\t\t
\r\n\t\t\t

Coffee break<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t11:25 – 12:00<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 1<\/strong> Anemia as a clinical problem, its impact on quality of life, and its role as a prognostic factor<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
\r\n\t\t\t

PART 2 |<\/span> Low-Risk MDS<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Ana Alfonso,<\/p>\r\n\t\t\t\t

Cl\u00ednica Universidad de Navarra. Pamplona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Isolda Fern\u00e1ndez,<\/p>\r\n\t\t\t\t

Centro de Hematolog\u00eda Pavlovsky. Buenos Aires, Argentina<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
11:25 – 11:45<\/div>\r\n\t\t
\r\n\t\t\t

Lower-risk MDS therapy: moving beyond quality of life toward overall survival<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Guillermo Garc\u00eda-Manero,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
11:45 – 12:00<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t12:00 – 13:35<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 2<\/strong> Immunotherapy<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Alessandro Isidori,<\/p>\r\n\t\t\t\t

Marche Nord Hospital. Pesaro, Italy<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Jordi Esteve,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednic de Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Joana Brioso Infante,<\/p>\r\n\t\t\t\t

Centro Hospitalar Universit\u00e1rio de Lisboa Norte, Portugal<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
12:00 – 12:20<\/div>\r\n\t\t
\r\n\t\t\t

Cellular therapy platforms in acute myeloid leukemias: where are we now and where are we going?<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Marion Subklewe,<\/p>\r\n\t\t\t\t

Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Germany<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
12:20 – 12:40<\/div>\r\n\t\t
\r\n\t\t\t

Is it time for CAR-T therapy in AML?<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Nela Klein-Gonz\u00e1lez,<\/p>\r\n\t\t\t\t

Hospital Clinic de Barcelona \u2013 IDIBAPS, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
12:40 – 13:00<\/div>\r\n\t\t
\r\n\t\t\t

Next generation CD19 CD3 bispecifics<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Alba Puyuelo,<\/p>\r\n\t\t\t\t

Hospital Universitario Vall d’Hebron. Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
13:00 – 13:20<\/div>\r\n\t\t
\r\n\t\t\t

Pivekimab<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Naval Daver,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
13:20 – 13:35<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
13:35 – 14:40<\/div>\r\n\t\t
\r\n\t\t\t

Lunch<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t

\r\n\t\t
\r\n\t\t\t13:35 – 14:15<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tLunch Session<\/strong> Mastocytosis<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Carlos Jim\u00e9nez-Chill\u00f3n,<\/p>\r\n\t\t\t\t

Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Adolfo de la Fuente,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center Madrid-Hospiten. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mayte Olave,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Universitario Lozano Blesa. Zaragoza, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t

\r\n\t\t
13:35 – 14:00<\/div>\r\n\t\t
\r\n\t\t\t

Multidisciplinary Symposium on Systemic Mastocytosis: When complexity calls for a shared vision: a symposium among experts on diagnosis and management<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. David Gonz\u00e1lez de Olano,<\/p>\r\n\t\t\t\t

Hospital Universitario Ram\u00f3n y Cajal. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Miguel Piris-Villaespesa,<\/p>\r\n\t\t\t\t

Hospital Universitario Ram\u00f3n y Cajal. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n\r\n\t

\r\n\t\t
14:00 – 14:15<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t14:40 – 15:30<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 3<\/strong> Daily challenges and complex decisions in Acute Leukemia<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. \u00c1ngela Figuera,<\/p>\r\n\t\t\t\t

Hospital de La Princesa. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Adolfo de la Fuente,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center Madrid-Hospiten, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Joaqu\u00edn S\u00e1nchez,<\/p>\r\n\t\t\t\t

Hospital Universitario Reina Sof\u00eda. C\u00f3rdoba, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
14:40 – 15:00<\/div>\r\n\t\t
\r\n\t\t\t

Hematologic neoplasms arising from donor cells<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Andr\u00e9s Jerez,<\/p>\r\n\t\t\t\t

Hospital Universitario Vall d’Hebron. Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
15:00 – 15:15<\/div>\r\n\t\t
\r\n\t\t\t

Clinical case<\/p>\r\n\t\t\t

Late IDH1-mutated isolated extramedullary relapse in myelodysplasia-related acute myeloid leukemia secondary to primary myelofibrosis: triplet therapy followed by second allogeneic hematopoietic stem cell transplantation.<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mar\u00eda Gaspar Rega\u00f1o,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
15:15 – 15:30<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n<\/div>\r\n \r\n

\r\n \r\n\t
\r\n\t\t
\r\n\t\t\t15:30 – 16:45<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 4<\/strong> AML-1 intensive chemotherapy vs. VEN+AZA<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Jordi Esteve,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednic de Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Anne Louise T\u00f8lb\u00f8ll S\u00f8rensen,<\/p>\r\n\t\t\t\t

Rigshospitalet Copenhagen University, Denmark<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mar\u00eda Marta Rivas,<\/p>\r\n\t\t\t\t

Hospital Universitario Austral. Buenos Aires, Argentina<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
15:30 – 15:50<\/div>\r\n\t\t
\r\n\t\t\t

The clue is in the details: the Paradigm study – design, patients and beyond<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Alexander Perl,<\/p>\r\n\t\t\t\t

Abramson Cancer Center \u2013 University of Pennsylvania. Philadelphia, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
15:50 – 16:10<\/div>\r\n\t\t
\r\n\t\t\t

Intensive QT<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Eduardo Rodr\u00edguez Arboli,<\/p>\r\n\t\t\t\t

Hospital Universitario Virgen del Roc\u00edo. Sevilla, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
16:10 – 16:30<\/div>\r\n\t\t
\r\n\t\t\t

Ven+Aza<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Irene S\u00e1nchez,<\/p>\r\n\t\t\t\t

Hospital Universitario La Paz. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
16:30 – 16:45<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t16:45 – 17:40<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 5<\/strong> MDS 2<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Joaqu\u00edn S\u00e1nchez,<\/p>\r\n\t\t\t\t

Hospital Universitario Reina Sof\u00eda. C\u00f3rdoba, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Claudia Sossa,<\/p>\r\n\t\t\t\t

Complejo M\u00e9dico Fundaci\u00f3n Oftalmol\u00f3gica de Santander – Cl\u00ednica Carlos Ardila Lulle (FOSCAL). Bucaramanga, Colombia<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Ana Alfonso,<\/p>\r\n\t\t\t\t

Cl\u00ednica Universidad de Navarra. Pamplona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
16:45 – 17:05<\/div>\r\n\t\t
\r\n\t\t\t

Bone marrow inflammation in MDS: a driver of clonal evolution and a therapeutic opportunity?<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Jos\u00e9 Miguel Torregrosa,<\/p>\r\n\t\t\t\t

Poitiers University Hospital, France<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
17:05 – 17:25<\/div>\r\n\t\t
\r\n\t\t\t

Progress and future outlook in CMML<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dra. Blanca Xicoy,<\/p>\r\n\t\t\t\t

ICO – Hospital Germans Trias i Pujol. Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
17:25 – 17:40<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
17:40 – 18:10<\/div>\r\n\t\t
\r\n\t\t\t

Coffee break<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t18:10 – 19:35<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 6<\/strong> AML-2 IDH1<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Margarida Coucelo,<\/p>\r\n\t\t\t\t

Unidade Local de Sa\u00fade de Coimbra, Portugal<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Claudia N\u00fa\u00f1ez-Torr\u00f3n,<\/p>\r\n\t\t\t\t

Hospital Universitario Infanta Sof\u00eda. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Mar\u00eda Marta Rivas,<\/p>\r\n\t\t\t\t

Hospital Universitario Austral. Buenos Aires, Argentina<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
18:10 – 18:25<\/div>\r\n\t\t
\r\n\t\t\t

BIG picture biology and early phase studies<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Adolfo de la Fuente,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center Madrid-Hospiten, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
18:25 – 18:40<\/div>\r\n\t\t
\r\n\t\t\t

The challenge of testing: isocitrate dehydrogenase-1 testing and first-line treatment in patients with European Leukaemia Network-defined AML ineligible for intensive therapy: a multi-country survey<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Alessandro Isidori,<\/p>\r\n\t\t\t\t

Marche Nord Hospital. Pesaro, Italy<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
18:40 – 18:55<\/div>\r\n\t\t
\r\n\t\t\t

Ivosidenib and azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who have an IDH1 gene mutation and are not eligible for intensive chemotherapy: the ALIDHE trial<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Susana Vives Polo,<\/p>\r\n\t\t\t\t

ICO – Hospital Universitario Germans Trias i Pujol. Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
18:55 – 19:10<\/div>\r\n\t\t
\r\n\t\t\t

The impact of sequencing in AML<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Rosa Mar\u00eda Ayala,<\/p>\r\n\t\t\t\t

Hospital Universitario 12 de Octubre. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t19:10 – 19:20<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tClinical Case<\/strong><\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t
\r\n\t\t
<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Miguel L\u00f3pez Esteban,<\/p>\r\n\t\t\t\t

Hospital Universitario Gregorio Mara\u00f1\u00f3n. Madrid, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n
19:20 – 19:35<\/div>\r\n
\r\n

Discussion<\/p>\r\n <\/div>\r\n <\/div>\r\n \r\n\t

\r\n\t\t
\r\n\t\t\t19:35 – 20:30<\/span>\r\n\t\t<\/div>\r\n\t\t
\r\n\t\t\tSESSION 7<\/strong> MDS 3<\/span>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n
\r\n\t\t
Chairs:<\/div>\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t

Dr. Mar Tormo,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Universitario de Valencia, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. M\u00f3nica Alejandra Romero,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednico Regional Dr. Guillermo Grant Benavente. Concepci\u00f3n, Chile<\/p>\r\n\t\t\t<\/div>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Virginia Abello,<\/p>\r\n\t\t\t\t

Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center. Bogot\u00e1, Colombia<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
19:35 – 19:55<\/div>\r\n\t\t
\r\n\t\t\t

New therapy for high-risk MDS in patients eligible for AloTPH<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Marina D\u00edaz,<\/p>\r\n\t\t\t\t

Hospital Cl\u00ednic de Barcelona, Spain<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
19:55 – 20:15<\/div>\r\n\t\t
\r\n\t\t\t

MRD in high-risk MDS: why we cannot simply copy the AML model<\/p>\r\n\t\t\t

\r\n\t\t\t\t

Dr. Guillermo Garc\u00eda-Manero,<\/p>\r\n\t\t\t\t

MD Anderson Cancer Center. Houston, USA<\/p>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n\t

\r\n\t\t
20:15 – 20:30<\/div>\r\n\t\t
\r\n\t\t\t

Discussion<\/p>\r\n\t\t<\/div>\r\n\t<\/div>\r\n \r\n<\/div>","protected":false},"excerpt":{"rendered":"09:30 – 09:40 Introduction and welcome 09:40 – 10:55 SESSION 1 Anemia as a clinical problem, its impact on quality of life, and its role as a prognostic factor PART 1 | Myelofibrosis: what are new drugs contributing to clinical practice? Chairs: Dr. Valent\u00edn Garc\u00eda Guti\u00e9rrez, Hospital Universitario Ram\u00f3n y Cajal. Madrid, Spain Dr. Gilberto … Leer m\u00e1s<\/a>","protected":false},"author":2,"featured_media":0,"parent":45,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-internas.php","meta":{"footnotes":""},"class_list":["post-98","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/98","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/comments?post=98"}],"version-history":[{"count":27,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/98\/revisions"}],"predecessor-version":[{"id":254,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/98\/revisions\/254"}],"up":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/pages\/45"}],"wp:attachment":[{"href":"https:\/\/www.doctaforum-events.org\/2026\/cursoleucemia2026\/wp-json\/wp\/v2\/media?parent=98"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}